Verucerfont |
Katalog-Nr.GC19374 |
Verucerfont ist ein Antagonist des Corticotropin-Releasing-Faktor-Rezeptors 1 (CRF1) mit IC50-Werten von ~6,1, >1000 und >1000nM fÜr CRF1, CRF2 bzw. CRF-BP.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 885220-61-1
Sample solution is provided at 25 µL, 10mM.
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.
Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (PPost hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline)[1].
References:
[1]. Schwandt ML, et al. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829.
Average Rating: 5
(Based on Reviews and 35 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *